Hasini Rathnayake

Hasini Rathnayake

Auto-generated profile, based on publicly available information

Hasini Rathnayake

School of Pharmacy and Medical Sciences, Griffith University, Gold Coast, Queensland, Australia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 December 2024 in BMJ Open
Verified
Journal Article
Open access
PDF file
HRHasini Rathnayake
Hasini Rathnayake
LHLuhao Han
Luhao Han
FCFabrício Da Silva Costa
Fabrício Da Silva Costa
CPCristiane Paganoti
Cristiane Paganoti
BDBrett Dyer
Brett Dyer
OHOlivia Holland
Olivia Holland
Objective Gestational diabetes mellitus (GDM) is a metabolic disorder associated with adverse maternal and neonatal outcomes. While GDM is diagnosed by oral glucose tolerance testing between 24–28 weeks, earlier prediction of risk of developing GDM via circulating biomarkers has the potential to risk-stratify women and implement targeted risk reduction before adverse obstetric outcomes. This scoping review aims to collate biomarkers associated with GDM development, associated perinatal outcome and medication requirement in GDM. Design The Preferred Reporting Items for Systematic Reviews and Meta-Analysis extension for scoping reviews was used to guide the study. Data sources This review searched for articles on PubMed, Embase, Scopus, Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature and the Web of Science from January 2013 to February 2023. Eligibility criteria The eligibility criteria included analytical observational studies published in English, focusing on pregnant women with maternal plasma or serum biomarkers collected between 6 and 24 weeks of gestation. Studies were excluded if they evaluated drug effects, non-GDM diabetes types or involved twin pregnancies, microbiota, genetic analyses or non-English publications. Data extraction and synthesis Two independent reviewers extracted data. One reviewer extracted data from papers included in the scoping review using Covidence. From the 8837 retrieved records, 137 studies were included. Results A total of 278 biomarkers with significant changes in individuals with GDM compared with controls were identified. The univariate predictive biomarkers exhibited insufficient clinical sensitivity and specificity for predicting GDM, perinatal outcomes, and the necessity of medication. Multivariable models combining maternal risk factors with biomarkers provided more accurate detection but required validation for use in clinical settings. Conclusion This review recommends further research integrating novel omics technology for building accurate models for predicting GDM, perinatal outcome, and the necessity of medication while considering the optimal testing time.

20 December 2024 in Respiratory Medicine
Verified
Journal Article
Open access
MAMadiha Ajaz
Madiha Ajaz
ISIndu Singh
Indu Singh
LVLada Vugic
Lada Vugic
RJRati Jani
Rati Jani
HRHasini Rathnayake
Hasini Rathnayake
NCNatalie J. Colson
Natalie J. Colson
Asthma is a chronic inflammatory disease and a leading cause of disability, posing a huge economic and social burden. Plant-based antioxidants have the potential to block proinflammatory pathways and protect against oxidative damage, which could improve asthma management. This review examines the role of plant-based antioxidants as adjuvant therapy on inflammatory markers and clinical outcomes of adults with asthma. Digital databases, including Scopus, MEDLINE, EMBASE, CINAHL, PsycINFO, and Cochrane Airway Group's Specialized Register of Trials, were searched. Two independent authors performed initial and full-text screening of identified papers. The criteria for study inclusion and exclusion were predefined. Two authors independently performed data extraction and risk of bias as per the PRISMA checklist. After full-text screening, nine randomized controlled trials were included in the final review. Seven of the included studies highlighted the efficacy of plant-based antioxidants in modulating the inflammatory cytokines in asthmatics. The benefits of antioxidants were also observed for improving oxidative status, lung functioning, and airway inflammatory markers. Furthermore, the overall quality of asthmatic patients' lives was improved with fewer exacerbations such as night coughs and wheezing. Despite having some limitations, the overall risk of bias was low in this review. The review indicated that plant-based antioxidants could have adjuvant beneficial effects in the management of asthma inflammatory markers, which may help improve asthma-related clinical outcomes. However, due to the small number of study subjects, further research is required on the effect of plant-based antioxidants on asthma-inflammatory markers and clinical outcomes.

20 December 2021 in Malaysian Journal of Nutrition
Verified
Journal Article
Open access
RRRathnayake Mudiyanselage Hasini Wasundara Rathnayake
Rathnayake Mudiyanselage Hasini Wasundara Rathnayake
JRJamburagoda Gamage Shirani Ranasinghe
Jamburagoda Gamage Shirani Ranasinghe
SSSeekkuge Susil Priyantha Silva
Seekkuge Susil Priyantha Silva

19 March 2026 in JMIR Preprints
Verified
Preprint
Open access
LHLuhao Han
Luhao Han
OHOlivia Holland
Olivia Holland
HRHasini Rathnayake
Hasini Rathnayake
CPCristiane Paganoti
Cristiane Paganoti
CRConrado Sávio Ragazini
Conrado Sávio Ragazini
FCFabrício Da Silva Costa
Fabrício Da Silva Costa
BACKGROUND Placental dysfunction underlies major obstetric complications, including preeclampsia, fetal growth restriction, preterm birth, and stillbirth. While early identification of pregnancies at high risk of complications enables preventive interventions, current screening methods based on traditional risk factors have limited accuracy. OBJECTIVE This project aims to develop robust prediction models for placental dysfunction-related pregnancy disorders and to determine the optimal delivery time by integrating maternal characteristics, biophysical measurements, and maternal circulating biomarkers. METHODS The Placental Health Study (PHS) is a prospective cohort study conducted at the Maternal Fetal Medicine (MFM) Unit at Gold Coast University Hospital (GCUH) in Queensland, Australia. Participants with singleton pregnancies enroll at one of three time points: 11–13 weeks, 26–28 weeks, and 35–36 weeks of gestation. Eligible participants who provide written informed consent are included and will also be invited to continue their participation through subsequent antenatal visits until delivery. Exclusion criteria are multiple pregnancies, major fetal anomalies, maternal age below 18 years, and inability to provide informed consent. Baseline and clinical data, including maternal demographics, obstetric and medical history, and current pregnancy records, will be collected. Each visit includes measuring maternal blood pressure and performing obstetric ultrasound with Doppler ultrasound to assess maternal, placental, and fetal indices and fetal biometry. Biological samples, including maternal serum, plasma, whole blood for RNA extraction, and urine, will be collected and processed for long-term storage at –80 ℃ for biomarker studies. Ethics approval has been granted by the Gold Coast Hospital and Health Service Human Research Ethics Committee (HREC/2022/QGC/84257) and Griffith University Human Research Ethics Committee (GU Ref No.2022/254). RESULTS Recruitment commenced in June 2022 and closed February 2026, with 1,267 participants enrolled, made up of 1,072 participants (84.6%) with a completed pregnancy and 144 participants (11.4%) still to complete their pregnancy, and the remaining 51 (4.0%) withdrawn or with missing/duplicated data. Clinical data have undergone preliminary cleaning and descriptive analysis, while biological samples are being processed for biomarker quantification and exploratory molecular analyses. Two to three publications are anticipated in late 2026 or early 2027, with ongoing analyses focused on biomarker discovery and integration with clinical and ultrasound parameters for prediction model development. CONCLUSIONS This cohort establishes a comprehensive database and biospecimen repository, collecting high-quality data and biological samples to advance research in predicting placental dysfunction-related pregnancy complications. Recruitment across three pregnancy stages integrates with routine clinical care, enhancing the feasibility and translation potential, while enabling the investigation of pregnancy progression and associated temporal changes. Although the single-center design may limit the sample size and generalizability of the findings to other settings and populations, the interdisciplinary research team brings diverse expertise that strengthens study depth and scope.

25 August 2026 in JMIR Research Protocols
Verified
Journal Article
Open access
LHLuhao Han
Luhao Han
OHOlivia Holland
Olivia Holland
HRHasini Rathnayake
Hasini Rathnayake
CPCristiane Paganoti
Cristiane Paganoti
CRConrado Sávio Ragazini
Conrado Sávio Ragazini
FCFabrício Da Silva Costa
Fabrício Da Silva Costa
Background: Placental dysfunction underlies major obstetric complications, including preeclampsia, fetal growth restriction, preterm birth, and stillbirth. While early identification of pregnancies at high risk of complications enables preventive interventions, current screening methods based on traditional risk factors have limited accuracy. Objective: This study aims to develop robust prediction models for placental dysfunction–related pregnancy disorders across 3 gestational windows and to determine the optimal delivery time by integrating maternal characteristics, biophysical measurements, and maternal circulating biomarkers. Methods: The Placental Health Study is a prospective cohort study conducted at the Maternal Fetal Medicine Unit at Gold Coast University Hospital, Australia. Singleton pregnancies are enrolled at 11 to 13 weeks, 26 to 28 weeks, and 35 to 36 weeks of gestation and are followed until delivery. Exclusion criteria are multiple pregnancies, major fetal anomalies, maternal age below 18 years, and inability to provide informed consent. Clinical data, standardized ultrasound and Doppler measurements, hemodynamic parameters, and biospecimens (serum, plasma, whole blood RNA, and urine) are collected at each visit. Three gestational age-specific datasets (11‐13 weeks, 26‐28 weeks, and 35‐36 weeks) will be constructed for model development. Prediction models will be developed using multivariable logistic regression. Competing risks (Fine and Gray) models will be used as sensitivity analyses for outcomes related to gestational age at delivery. Bayesian updating will be applied to refine existing Fetal Medicine Foundation risk estimates using additional biomarkers or variables collected later in pregnancy. Developed models will undergo internal validation via 5-fold cross-validation, with performance assessed through model discrimination, calibration, and comparison against existing approaches. Collected biospecimens will also be analyzed for angiogenic markers and exploratory omics studies. Results: Recruitment occurred from June 2022 to February 2026, enrolling 1267 participants. As of submission, 1072 (84.6%) participants have completed their pregnancies, 144 (11.4%) participants remain active in follow-up, and 51 (4%) were withdrawn or had missing or duplicated data. Clinical data have undergone preliminary cleaning and descriptive analysis. Biospecimens are being processed for biomarker quantification and exploratory molecular analyses. Two to three publications are anticipated in late 2026 or early 2027. Conclusions: This cohort establishes a comprehensive database and biospecimen repository to advance prediction of placental dysfunction–related complications. Three-stage recruitment integrated into routine clinical care enhances feasibility and translation potential, enabling dynamic risk assessment and investigation of temporal biomarker changes. Although the single-center design may limit generalizability, warranting future external validation, the interdisciplinary research team brings diverse expertise that strengthens study depth and scope.

Verified
Journal Article
Open access
RRR.M. Hasini Wasundara Rathnayake
R.M. Hasini Wasundara Rathnayake
NÇNursen Çoruh
Nursen Çoruh
The prevalence of bronchial asthma increases and possesses a socioeconomic impact on a person's life. It is a complex disease where environmental factors, oxidative damage, and genetic factors are responsible for modulating the initiation and the progression of the disease. Reactive Oxygen Species (ROS) and Reactive Nitrogen Species (RNS) are responsible for the oxidative damage in bronchial asthma and those are produced by living organisms as a result of normal cellular metabolism and environmental factors, such as air pollutants or cigarette smoke. The pathogenesis of the bronchial asthma is initiated by ROS/RNS which can damage cell structures such as carbohydrates, nucleic acids, lipids, and proteins and alter their functions. The alteration in the balance between oxidants and antioxidants is termed "oxidative stress". Aerobic organisms have integrated antioxidant systems, which include enzymatic and non-enzymatic antioxidants that are usually effective in blocking the harmful effects of ROS /RNS in bronchial asthma. However, in pathological conditions, the antioxidant systems can be overwhelmed. In this review, it summarizes the evidence, biomarkers, prevention, and management of bronchial asthma induced by the oxidative stress of ROS/RNS.